StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
Research context
StemRIM appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
StemRIM is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 70.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.7.
StemRIM's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 108.9% to $-515M since the same quarter in the previous year.
Based on the above factors, StemRIM gets an overall score of 1/5.